Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma

This study utilizes a prospective, multicenter, randomized two-arm design to evaluate the efficacy and safety of the etoposide, cytarabine, and pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) combination therapy (EAP regimen) in mobilizing hematopoietic stem cells in patients with non-Hodgkin's lymphoma (NHL). A total of 99 NHL patients will be enrolled as research subjects and will be randomly allocated in a 2:1 ratio to compare the EAP regimen versus disease-specific chemotherapy mobilization regimen. The primary endpoint is the proportion of patients achieving the ideal collection value after a single collection (CD34+ cells ≥5×10\^6/kg).

NCT Number	NCT06520163
Lead Sponsor	The Affiliated People's Hospital of Ningbo University Collaborators: First Affiliated Hospital of Zhejiang University, First Affiliated Hospital of Wenzhou Medical University, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Jinhua People's Hospital, The Central Hospital of Lishui City, Shaoxing People's Hospital, Shaoxing Second Hospital, Zhejiang Provincial Tongde Hospital, Taizhou Hospital, Dongyang People's Hospital, Affiliated Hospital of Jiaxing University, Huzhou Central Hospital, Second Affiliated Hospital of Wenzhou Medical University, Ningbo Medical Center Lihuili Hospital, Jinhua Municipal Central Hospital
Conditions	Non-Hodgkin's Lymphoma, Hematopoietic Stem Cell Mobilization
Enrollment	99 participants
Start Date	2024-08-01
Primary Completion	2026-08 (estimated)
Study Completion	2026-08 (estimated)
Updated on ClinicalTrials.gov	2025-12-04